Biogen’s salanersen has shown promise in slowing neuronal damage and opening new motor milestones, according to interim ...

Panelists discuss how spinal muscular atrophy (SMA) treatment will evolve over the next 5 years, likely incorporating ...

Panelists discuss how communication between clinicians, patients, and payers could improve equitable access to spinal ...

Antisense-based therapy salanersen (BIIB115/ION306) is a possible follow-up to Biogen's big-selling Spinraza (nusinersen) therapy for SMA, which has come under pressure from increased competition in ...

He emphasized that residential investment will be crucial for overall GDP growth, as current CapEx spending in the US is ...

Google DeepMind has launched AlphaGenome, an advanced DNA-reading AI model that can predict the impact of genetic mutations ...

Sarcopenia, which is a progressive and extensive decline in muscle mass and strength, is common with aging and is estimated ...

US insurance giant Cigna has taken fresh legal action against Bristol Myers Squibb (NYSE: BMY), accusing the drugmaker of ...

ISS-based lab-on-a-chip model advances the understanding of muscle aging and degeneration in microgravity, guiding future therapeutic strategies.

Living with SMA isn't just about survival, says columnist. There's also the emotional weight of preparing for the next crisis ...